- Notification that Quarterly Report will be submitted late (NTN 10Q)
20 März 2012 - 11:03AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM
12B-25
SEC File Number: 000-28761
CUSIP Number: 14160X 203
NOTIFICATION OF LATE FILING
(Check
One):
|
¨
Form
10-K
|
¨
Form
11-K
|
¨
Form
20-F
|
x
Form 10-Q
|
¨
Form
N-SAR
|
For Period Ended:
|
Quarter ended January 31, 2012
|
¨
|
Transition Report on Form 10-K
|
¨
|
Transition Report on Form 10-Q
|
¨
|
Transition Report on Form 20-F
|
¨
|
Transition Report on Form N-SAR
|
¨
|
Transition Report on Form 11-K
|
|
|
For the Transition Period Ended:
|
|
Read attached instruction
sheet before preparing form. Please print or type.
Nothing in this form
shall be construed to imply that the Commission has verified any information contained herein.
If the
notification relates to a portion of the filing checked above, identify the item(s) to which the notification relates: _____________________________________________________________________________________________________
PART I
REGISTRANT INFORMATION
Full name of Registrant
|
CardioGenics Holdings Inc.
|
Former name if applicable
|
|
Address of principal executive office
(Street and Number)
|
6295 Northam Drive, Unit 8
|
City, state and zip code
|
Mississauga, Ontario L4V 1WB
|
PART II
RULE 12b-25 (b)
AND
(c)
If the subject report
could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following
should be completed. (Check box if appropriate.)
x
|
(a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
|
|
|
¨
|
(b) The subject annual report, semi-annual report, transition report on Form 10-K, 20-F, 11-K or Form N-SAR, or portion thereof will be filed on or before the 15th calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or portion thereof will be filed on or before the 5th calendar day following the prescribed due date; and
|
|
|
¨
|
(c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
|
PART III
NARRATIVE
State below in reasonable
detail the reasons why Forms 10-K, 11-K, 20-F, 10-Q, N-SAR or the transition report portion thereof could not be filed within the
prescribed time period. (Attach extra sheets if needed).
Records and documentation necessary for
completion of the narrative and financial statements for the report were not available in time to complete the Form 10-Q of the
Registrant for the quarterly period ended January 31, 2012 as on March 16, 2012, the Board of Directors of CardioGenics Holdings
Inc. (the "Company"), after consultation with and upon the recommendation of management, concluded that the Company's
previously issued audited financial statements as of and for the year ended October 31, 2011, as presented in the Company's Form
10-K for that same period are misstated.
Management will work with the current auditor
of the Company to audit the restatement as soon as practicable.
PART IV
OTHER INFORMATION
|
(1)
|
Name and telephone number of person to contact in regard to this notification
|
Yahia Gawad
|
|
(905)
|
|
673-8501
|
(Name)
|
|
(Area Code)
|
|
(Telephone Number)
|
(2) Have all other
periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company
Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been
filed? If the answer is no, identify report(s).
x
Yes
¨
No
(3) Is it anticipated
that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by
the earnings statements to be included in the subject report or portion thereof?
x
Yes
¨
No
If so: attach an explanation
of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate
of the results cannot be made.
The financial statements for the year ended
October 31, 2011, will be restated to reflect the issuance in the year of warrants which were granted on a fully vested nonforfeitable
basis as an expense of $1.5 million for the year and a resultant write off of the prepaid asset set up which relates to these warrants.
In addition, the recording of certain tax related income and expenses, netting to an approximate income of $40,000 will also be
reflected.
CardioGenics Holdings Inc.
|
(Name of Registrant as Specified in Charter)
|
has caused this notification to be signed
on its behalf by the undersigned thereunto duly authorized.
Date
|
March 19, 2012
|
|
By:
|
/s/ Yahia Gawad
|
|
|
|
|
Name:
|
Yahia Gawad
|
|
|
|
|
Title:
|
Chief Executive Officer
|
CardioGenics (CE) (USOTC:CGNH)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
CardioGenics (CE) (USOTC:CGNH)
Historical Stock Chart
Von Jul 2023 bis Jul 2024